The ones who attended the recent CannX-2022 conference heard a lot about the overwhelming medical benefits of cannabis.
The need for evidence-based clinical trials was voiced loudly. In general, Israel is a well known for conducting high quality clinical trials. Although the approval process for cannabis clinical trials is challenging, we believe that prior knowledge and proper planning could be of benefit when Israel is chosen to participate is such clinical trials.

For initial guidance and recommendations:
https://gcp.co.il/publication/clinical-trials-with-cannabis-guidance-for-approval-process-in-israel/

The professional team at GCP Clinical Studies will be happy to guide you through the local regulatory requirements and help you plan and manage your clinical trial.

CannX 2022

It has been two days full of exciting sessions, interesting discussions with leading scientists and experts in the field, and an overall invaluable experience for all of us!

Thank you all for being with us and being a part of the advancement of medical cannabis!
See you at CannX 2023.

IdentifAI Genetics is proud to announce the launching of strategic cooperation with Mor Research Applications, a Division of Clalit Health Services, the largest HMO in Israel and one of the most prominent health organizations globally.
 

Clalit’s top clinicians and researchers are ideal partners in our journey. Mor and Clalit’s endorsement and involvement constitute a first-rate seal of approval for IdentifAI’s mission to present a new generation of prenatal genetic testing platform.